Fibrosis focus Undertake targeted outreach to fibrosis-focused payers, KOLs, and biotech incubators highlighting ENV-101's Hedgehog pathway inhibition for IPF and PPF, aligning with the company's clinical-stage status and recent ATS 2025 poster presentations.

ADC and HER3 Position ENV-501 as a differentiated HER3-targeted ADC for HER3-positive solid tumors to engage oncology partners and potential co-development opportunities, leveraging the recent Series C funding to support expansion.

Strategic financing Leverage the $133M Series C momentum to approach strategic investors and potential collaborators interested in fibrosis and targeted cancer therapies, offering collaboration on clinical development and manufacturing scale-up.

Leadership visibility Engage executive and medical leadership (e.g., CMO appointment and board additions) to foster partnerships with academic centers, patient advocacy groups, and contract research organizations for trial sites and recruitment.

Clinical progress visibility Monitor and respond to new data, posters, and conference activities (ATS 2025) to time outreach for potential co-development discussions, regulatory strategy support, and potential licensing discussions in fibrosis and oncology.